Global Health growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+19.5%	+17.8%
EBITDA	+4.8%	+14.5%
Net Income	+15.1%	+19.3%
EPS (adj.)	+15.6%	+19.5%
Total Assets	+23.9%	+12.8%
Total Equity	+17.6%	+17.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDANTA₹1,299.70

Global Health Ltd.

· Pharma & Health

₹ CrorePeersMAXHEALTH APOLLOHOSP FORTIS GLAXO ANTHEM AJANTPHARM IPCALAB ABBOTINDIAMcap ₹34,922 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+19.5	+17.8
EBITDA	+4.8	+14.5
Net Income	+15.1	+19.3
EPS (adj.)	+15.6	+19.5
Total Assets	+23.9	+12.8
Total Equity	+17.6	+17.9

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.